Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1995
Net Income	-9.81	-13.6	-12.95	-10.02	-11.65	-14	-7.02	-5.02	-1.38	-9.61	Upgrade
Depreciation & Amortization	0.05	0.04	0.06	0.09	0.05	0.02	0.04	0.03	0.01	0	Upgrade
Share-Based Compensation	4.51	6.1	7.5	3.92	5.52	8.59	1.71	0.87	2.72	3.23	Upgrade
Other Operating Activities	-0.96	0.96	0.45	-0.17	1.34	1.11	-0.54	0.73	0.01	3.99	Upgrade
Operating Cash Flow	-6.21	-6.49	-4.94	-6.18	-4.74	-4.27	-3.8	-3.38	1.36	-2.38	Upgrade
Capital Expenditures	0	0	0.04	-0.02	-0.18	-0.04	0.01	-0.15	-0.05	-0.01	Upgrade
Acquisitions	0	0	0.01	0	0	0	0	0	0	0	Upgrade
Change in Investments	-5.6	-10.73	-3.96	-0.29	-0.35	1.5	-2.75	1.65	0.1	-2.5	Upgrade
Investing Cash Flow	-5.6	-10.73	-3.92	-0.31	-0.53	1.46	-2.74	1.5	0.05	-2.51	Upgrade
Share Issuance / Repurchase	0.37	0.45	31.57	9.41	5.69	2.53	10.88	0.03	-0.4	4.05	Upgrade
Debt Issued / Paid	0	0	0	0	0	0	-3	0	0	3.5	Upgrade
Other Financing Activities	-	-	-	-	0.01	-	-0.5	-0.04	-	-0.2	Upgrade
Financing Cash Flow	0.37	0.45	31.57	9.41	5.7	2.53	7.38	-0	-0.4	7.35	Upgrade
Net Cash Flow	-11.45	-16.77	22.71	2.93	0.44	-0.28	0.85	-1.88	1.01	2.46	Upgrade
Free Cash Flow	-6.21	-6.49	-4.9	-6.19	-4.92	-4.31	-3.78	-3.53	1.31	-2.39	Upgrade
Free Cash Flow Margin	-2956.67%	-	-957.62%	-	-1966.75%	-387.58%	-1043.28%	-1176.07%	14.14%	-65.06%	Upgrade
Free Cash Flow Per Share	-0.20	-0.21	-0.17	-0.28	-0.25	-0.24	-0.31	-0.40	0.15	-0.27	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).